Cargando…
The Economic Burden of Chronic Myeloid Leukemia in Patients with Later Lines: Findings from a Real-World Analysis in Italy
INTRODUCTION: Chronic myeloid leukemia (CML) is a hematopoietic myeloproliferative disorder that accounts for 20% of all leukemias of adults. The introduction of tyrosine kinase inhibitors (TKIs) (imatinib, bosutinib, dasatinib, nilotinib, ponatinib) has yielded significant benefits for patients wit...
Autores principales: | Breccia, Massimo, Chiodi, Francesca, Nardozza, Aurelio Pio, Valsecchi, Diletta, Perrone, Valentina, Sangiorgi, Diego, Giacomini, Elisa, Rendace, Maria Chiara, Coco, Paola, Premoli, Eleonora, Degli Esposti, Luca |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9989002/ https://www.ncbi.nlm.nih.gov/pubmed/36562943 http://dx.doi.org/10.1007/s12325-022-02398-6 |
Ejemplares similares
-
Real-World Analysis of the Therapeutic Management and Disease Burden in Chronic Myeloid Leukemia Patients with Later Lines in Italy
por: Breccia, Massimo, et al.
Publicado: (2022) -
Real-World Evidence on Disease Burden and Economic Impact of Sickle Cell Disease in Italy
por: De Franceschi, Lucia, et al.
Publicado: (2022) -
Real-World Evaluation of the Management, Treatment Pathways and Outcome of Melanoma Patients with Target Therapies in Italy
por: Marcon, Ilaria Gioia, et al.
Publicado: (2023) -
Burden of Illness in Follicular Lymphoma with Multiple Lines of Treatment, Italian RWE Analysis
por: Ferreri, Andrés J. M., et al.
Publicado: (2023) -
Effects of hyperkalaemia and non‐adherence to renin–angiotensin–aldosterone system inhibitor therapy in patients with heart failure in Italy: a propensity‐matched study
por: Volterrani, Maurizio, et al.
Publicado: (2020)